Drugs targeting FCAR may play a role in the late phase of MI by modulating the immune response, whereas drugs targeting MMP9 are expected to improve cardiac function by reducing myocardial fibrosis and potentially by modulating the activity of associated immune cells like neutrophils and macrophages (Nian et al., 2023; Gentek and Hoeffel, 2017). The gene discussed is MMP9; the disease is Myocardial fibrosis.